-
Avastin not as beneficial to older lung cancer patients
-
1:28
-
Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, comments on a
study that found adding the drug bevacizumab (Avastin) to the standard
chemotherapy regimen for non-small cell lung cancer did not lead to
significantly increase survival rates for patients over the age of 65
enrolled in Medicare. Based on these results, the authors recommend that
bevacizumab should not automatically be administered together with
carboplatin-paclitaxel for older patients with non-small cell lung
cancer. Rather, clinicians should exercise caution in making treatment
recommendations and use bevacizumab judiciously for their patients.
Tags: chemotherapy, LungCancer